icon-folder.gif   Conference Reports for NATAP  
The Liver Meeting
Boston MA
November 2016
Back grey_arrow_rt.gif
The Safety and Tolerability of Sofosbuvir/Velpatasvir With Weight-Based Ribavirin in Patients With Child-Pugh Turcotte Class B Cirrhosis in the ASTRAL-4 Study
  Reported by jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Michael R. Charlton,1 Robert S. Brown, Jr,2 Gregory T. Everson,3 Mitchell L. Shiffman,4 Myron J. Tong,5 Mark S. Sulkowski,6 Di An,7 Lingling Han,7 Anu O. Osinusi,7 John McNally,7 Diana M. Brainard,7 G. Mani Subramanian,7 Jacqueline G. O'Leary,8 Michael P. Curry9
1Intermountain Medical Center, Murray, UT; 2Weill Cornell Medicine, New York, NY; 3University of Colorado Anschutz Medical Campus, Aurora, CO; 4Liver Institute of Virginia, Richmond, VA; 5Huntington Medical Research Institutes, Pasadena, CA; 6Johns Hopkins University, Baltimore, MD; 7Gilead Sciences, Inc., Foster City, CA; 8Baylor University Medical Center at Dallas, TX; 9Beth Israel Deaconess Medical Center, Boston, MA








1. Curry M, et al. N Engl J Med 2015;373:2618-28; 2. Charlton M, et al. Gastroenterology 2015;149:649-59; 3. Manns M, et al. Lancet Infect Dis 2016;16:685-97; 4. Poordad F, et al. Hepatology 2016;63:1493-505;
5. Epclusa [prescribing information]. Foster City, CA: Gilead Sciences, Inc., June 2016; 6. Epclusa [SmPC]. Foster City, CA: Gilead Sciences, Inc., July 2016.